Nuo Therapeutics, Inc. (AURX) director and 10% owner Scott M. Pittman acquired warrants on October 6, 2026, covering 4,500 shares of common stock and a Prepayment Restated Warrant covering a maximum of 458 shares. Both warrants have an exercise price of $1.50 per share and expire January 23, 2031.
The 4,500-share warrant was issued in connection with the assumption of a portion of an assigned funding commitment. The 458-share warrant represents the maximum shares issuable, if at all, in the event of a Prepayment; it vests, if at all, upon a Prepayment, no later than December 31, 2027.
Nuo Therapeutics, Inc. (AURX) closed the $325,000 Second Funding under its loan agreement on October 6, 2026, receiving the full amount. Aggregate funding received under the agreement is $2,000,000, matching the stated total commitment. The amendment set October 6 as the closing date and allowed a lender to assign $100,000 of its commitment; four lenders assumed equal $25,000 portions, including three new unaffiliated lenders and Scott M. Pittman, a director and more than 10% beneficial owner.
The notes bear 12% annual interest, payable in warrants, and mature December 31, 2028. For the assigned $100,000 commitment, the company issued warrants exercisable for 18,000 shares immediately and 1,832 shares subject to contingent vesting, and agreed to issue Interest Warrants for up to 11,000 shares at maturity or earlier voluntary or mandatory prepayment. For his additional $25,000 loan, Pittman received warrants for 4,500 immediately exercisable shares, 458 shares subject to contingent vesting, and up to 2,750 Interest Warrant shares. The amendment did not change other material loan terms or the warrants’ exercise price, expiration date, or other material economic terms.
Nuo Therapeutics, Inc. (AURX) reported that CEO/CFO David Emerson Jorden purchased Common Stock in two open-market transactions. On 2026-08-28, he bought 7,984 shares at a weighted average price of $1.089 per share, from $1.08–$1.10. On 2026-08-27, he purchased 789 shares at $1.07 per share. The filing’s Rule 10b5-1 checkbox is not marked as being under a trading plan.
Nuo Therapeutics, Inc. (AURX) reported that its CEO/CFO, Jorden David Emerson, acquired shares of the company’s common stock in two Form 4-reported transactions. On 2026-08-28, he acquired 7,984 shares at a weighted average price of $1.089 per share, executed in multiple trades between $1.08 and $1.10. On 2026-08-27, he acquired an additional 789 shares at $1.07 per share. These are reported as grant/award or other acquisitions, and post-transaction share holdings are not stated in this filing.
Nuo Therapeutics, Inc. reported sharply higher revenue for the quarter ended June 30, 2026 and a smaller loss while updating on key commercial and financing developments. For the second quarter, total revenue was $1,768,986, up from $700,202 a year earlier, driven mainly by product sales growth. Gross profit increased to $1,170,027, and the quarterly net loss narrowed to $277,601 from $649,689, with loss per share steady at $0.01.
For the first half of 2026, revenue rose to $3,071,101 from $1,184,583, while the net loss improved to $896,067 from $1,395,817. The balance sheet shows total assets of $2,626,290 and total liabilities of $4,161,604, resulting in a stockholders’ deficit of $1,535,314. Management highlighted continued positive performance of the Smith+Nephew private label arrangement, confirmation of a reimbursement fee milestone expected to be paid this quarter, and an amended loan agreement providing additional working capital with an option to increase total borrowings on September 30, 2026 as the company works toward breakeven operations.
Nuo Therapeutics, Inc. develops and markets the Aurix autologous platelet-rich plasma system for chronic wound care. For the quarter ended June 30, 2026, it generated $1.77 million in revenue, up sharply from $0.70 million a year earlier, with gross profit of $1.17 million and a net loss of $0.28 million. Six‑month revenue rose to $3.07 million, and the net loss narrowed to $0.90 million from $1.40 million.
Growth was driven by higher Aurix sales, new private-label sales under the Smith+Nephew distribution agreement, and recognition of $0.16 million in distribution fee revenue. However, aggregate gross margin declined to about 66% due to low‑margin centrifuge device sales and lower margins on private‑label kits.
Liquidity remains constrained. As of June 30, 2026, cash was $0.45 million versus current liabilities of $1.55 million, notes payable totaled $1.75 million, and stockholders’ deficit was $1.54 million with an accumulated deficit of roughly $35.7 million. The company states that substantial doubt exists about its ability to continue as a going concern and is relying on secured promissory notes, bearing interest at 12% and accompanied by equity warrants, while it seeks additional capital. Management also discloses a supply interruption in a key bovine thrombin reagent and notes that although a short‑term alternative has been identified, longer‑term sourcing and regulatory solutions are still being pursued.
Nuo Therapeutics, Inc. reported that CSO/COO Peter Clausen received a grant of options to purchase 65,000 shares of common stock. The options have an exercise price of $1.01 per share and expire on June 29, 2036.
According to the disclosure, one third of these options become exercisable as of June 30, 2027, with the remaining balance vesting quarterly over the following two years. After this grant, Clausen holds options for 65,000 underlying shares directly, reflecting a compensation-related award rather than an open-market trade.
Nuo Therapeutics CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 on June 30, 2026 through a net exercise that delivered 1,608 common shares after 160,892 shares were withheld at $1.01 for exercise price and taxes. He also received a grant of 125,000 options at $1.01 on June 29, 2026, expiring June 29, 2036, with one third exercisable as of June 30, 2027 and the balance vesting quarterly over the following two years. Following these updates and a 25,381-share correction from a prior report, he directly holds 2,061,227 common shares and 125,000 options.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported a compensation-related option exercise and new option grant. He exercised options for 40,000 shares of common stock at $1.00 per share. In a net share settlement, the issuer withheld 39,604 shares at a closing price of $1.01 to cover the exercise cost, and Pittman received 396 net shares.
After the transactions, he directly owns 5,440,000 shares of common stock. He also received a new grant of options for 30,000 shares with an exercise price of $1.01 per share that fully vest as of June 30, 2027 and expire on June 29, 2036. These actions reflect routine equity compensation and tax withholding rather than open-market trading.
Nuo Therapeutics director C. Eric Winzer reported routine equity compensation transactions. On June 30, he exercised stock options for 40,000 shares of common stock at $1.00 per share. The issuer withheld 39,604 shares at the closing price of $1.01 to cover the exercise cost, leaving him with 396 newly issued shares.
Following these transactions, Winzer directly held 173,050 shares of common stock. He also received a new option grant on June 29 for 30,000 shares of common stock at an exercise price of $1.01 per share, vesting fully by June 30, 2027 and expiring on June 29, 2036.